ArticleAntimicrobial agents and chemotherapy2005
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 100 citations in OpenAlex.
- Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.PLoS medicine · 2006Trial
- A Dual-Reporter Fluorescence-Luminescence Assay for Drug Screening in Promastigote and Intracellular Amastigote Stages ofMolecules (Basel, Switzerland) · 2026Article
- Molecular, structural, and functional characterization of delta subunit of T-complex protein-1 fromInfection and immunity · 2024Article
- Anti-Antimicrobial agents and chemotherapy · 2024Article
- Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis,RSC medicinal chemistry · 2023Article
- Article
- Discovery of 2,3-dihydro-1RSC medicinal chemistry · 2022Article
- Reporter gene systems: A powerful tool forCurrent research in microbial sciences · 2022Article
- Challenges and Tools for In VitroPathogens (Basel, Switzerland) · 2021Review
- Efficient antileishmanial activity of amphotericin B and piperine entrapped in enteric coated guar gum nanoparticles.Drug delivery and translational research · 2021Article
- Development of a Fluorescent Assay to Search New Drugs Using Stable tdTomato-Frontiers in cellular and infection microbiology · 2021Article
- Antileishmanial assessment of isoxazole derivatives againstRSC medicinal chemistry · 2020Article
- TCP1γ Subunit Is Indispensable for Growth and Infectivity of Leishmania donovani.Antimicrobial agents and chemotherapy · 2020Article
- Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria.Marine drugs · 2020Review
- Transcriptional responses of Leishmania (Leishmania) amazonensis in the presence of trivalent sodium stibogluconate.Parasites & vectors · 2019Article
- New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence.PLoS neglected tropical diseases · 2017Article
- MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex.Scientific reports · 2017Article
- Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.Antimicrobial agents and chemotherapy · 2017Article
- In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.The Korean journal of parasitology · 2015Article
- MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently available primary screens for the selection of candidate antileishmanial compounds are not ideal. These techniques are time-consuming, laborious, and difficult to scale and require macrophages, which limit their use for high-throughput screening. We have developed Leishmania donovani field isolates that constitutively express the firefly luciferase reporter gene (luc) as a part of an episomal vector. An excellent correlation between parasite number and luciferase activity was observed. luc expression was stable, even in the absence of drug selection, for 4 weeks. The transfectants were infective to macrophages, and intracellular amastigotes exhibited luciferase activity. The suitability of these recombinant field isolates for in vitro screening of antileishmanial drugs was established. The luciferase-expressing sodium stibogluconate-resistant cell lines offer a model for the screening of compounds for resistance. The system is in routine use at the Central Drug Research Institute, Lucknow, India, for high-throughput screening of newly synthesized compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.